{
    "paper_id": "d1f0873a0b19ae4b3a7617ad8a5cf412cc6adfbb",
    "metadata": {
        "title": "Letter to the Editors in Response to: Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers may be harmful in patients with diabetes during COVID-19 pandemic (Cure et al.)",
        "authors": [
            {
                "first": "Timur",
                "middle": [],
                "last": "Ekiz",
                "suffix": "",
                "affiliation": {},
                "email": ""
            },
            {
                "first": "Murat",
                "middle": [],
                "last": "Kara",
                "suffix": "",
                "affiliation": {
                    "laboratory": "",
                    "institution": "Hacettepe University Medical School",
                    "location": {
                        "settlement": "Ankara",
                        "country": "Turkey"
                    }
                },
                "email": ""
            },
            {
                "first": "Levent",
                "middle": [],
                "last": "\u00d6z\u00e7akar",
                "suffix": "",
                "affiliation": {
                    "laboratory": "",
                    "institution": "Hacettepe University Medical School",
                    "location": {
                        "settlement": "Ankara",
                        "country": "Turkey"
                    }
                },
                "email": ""
            }
        ]
    },
    "abstract": [],
    "body_text": [
        {
            "text": "We read with great interest the article by Cure et al. [1] in Diabetes and Metabolic Syndrome: Clinical Research and Reviews. The authors commented about the possible harmful effects of angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs) in patients with diabetes mellitus during the COVID-19 pandemic.",
            "cite_spans": [
                {
                    "start": 55,
                    "end": 58,
                    "text": "[1]",
                    "ref_id": "BIBREF0"
                }
            ],
            "ref_spans": [],
            "section": "Dear Editor,"
        },
        {
            "text": "While we congratulate them for having tried to study this debated issue; we, herein, wish to advocate the possible ''beneficial'' roles of these drugs as well.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Dear Editor,"
        },
        {
            "text": "Since hypertension is one of the most significant risk factors for severe disease and mortality in COVID-19 and ACE2 is the entry receptor of 2 SARS-CoV-2 [1, 2] , the renin angiotensin system (RAS) has received much focus [1, 2] . First, based on a few animal studies showing increased ACE2 expression due to RAS inhibitors, it is yet quite skeptical to discontinue RAS inhibitors, particularly in high-risk patients [2] . Further, a recent study has shown the protective effects of ACEIs/ARBs against mortality in COVID-19 [3] . ACEIs/ARBs users (almost 20% had diabetes mellitus) had lower risk of all-cause mortality [3] .",
            "cite_spans": [
                {
                    "start": 155,
                    "end": 158,
                    "text": "[1,",
                    "ref_id": "BIBREF0"
                },
                {
                    "start": 159,
                    "end": 161,
                    "text": "2]",
                    "ref_id": null
                },
                {
                    "start": 223,
                    "end": 226,
                    "text": "[1,",
                    "ref_id": "BIBREF0"
                },
                {
                    "start": 227,
                    "end": 229,
                    "text": "2]",
                    "ref_id": null
                },
                {
                    "start": 418,
                    "end": 421,
                    "text": "[2]",
                    "ref_id": null
                },
                {
                    "start": 525,
                    "end": 528,
                    "text": "[3]",
                    "ref_id": "BIBREF3"
                },
                {
                    "start": 621,
                    "end": 624,
                    "text": "[3]",
                    "ref_id": "BIBREF3"
                }
            ],
            "ref_spans": [],
            "section": "Dear Editor,"
        },
        {
            "text": "Second, ACEI/ARB should actually be considered separately -as they inhibit different steps in the classical RAS pathway. ACEIs inhibit the step from angiotensin I to angiotensin II, whereas ARBs block angiotensin II type I (AT1) receptor. Indeed, both inhibit the deleterious effects of the classical pathway (i.e. angiotensin II/AT1 receptor interaction) such as peripheral vasoconstriction, skeletal muscle atrophy, fibrosis, and increased insulin resistance. However, ACEIs perform a multilevel block in both classical and non-classical pathways, which result in a strong augmentation of the non-classical pathway (i.e. angiotensin 1-7/Mas receptor axis). This activation also causes positive effects on the skeletal muscle anabolic processes. Lastly, ACEIs decrease the degradation of bradykinin, a potent vasodilator, and thus enhance the perfusion of different soft tissues including the muscle [4] .",
            "cite_spans": [
                {
                    "start": 901,
                    "end": 904,
                    "text": "[4]",
                    "ref_id": "BIBREF5"
                }
            ],
            "ref_spans": [],
            "section": "Dear Editor,"
        },
        {
            "text": "In this sense, another noteworthy example for the protective effects of ACEIs/ARBs would be the improvement of sarcopenia (age-related loss of muscle mass/function).",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Dear Editor,"
        },
        {
            "text": "Inhibition of the RAS activity exerts vasodilator, anti-hypertrophic, and anti-fibrotic effects on muscles [4] . It has been shown that ACEI users had higher lower extremity muscle mass than those using other antihypertensive drugs. For instance, in a three-year longitudinal study, ACEIs prevented the decline in knee extensor strength and gait speed [5] .",
            "cite_spans": [
                {
                    "start": 107,
                    "end": 110,
                    "text": "[4]",
                    "ref_id": "BIBREF5"
                },
                {
                    "start": 352,
                    "end": 355,
                    "text": "[5]",
                    "ref_id": "BIBREF6"
                }
            ],
            "ref_spans": [],
            "section": "Dear Editor,"
        },
        {
            "text": "Accordingly, we simply highlight that increased RAS activity causes both hypertension and sarcopenia; and ACEI (and possibly ARB) use can actually be preventive for both conditions during the Covid-19 pandemic.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Dear Editor,"
        }
    ],
    "bib_entries": {
        "BIBREF0": {
            "ref_id": "b0",
            "title": "Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers may be harmful in patients with diabetes during COVID-19 pandemic",
            "authors": [
                {
                    "first": "E",
                    "middle": [],
                    "last": "Cure",
                    "suffix": ""
                },
                {
                    "first": "Cumhur",
                    "middle": [],
                    "last": "Cure",
                    "suffix": ""
                },
                {
                    "first": "M",
                    "middle": [],
                    "last": "",
                    "suffix": ""
                }
            ],
            "year": 2020,
            "venue": "Diabetes Metab Syndr",
            "volume": "14",
            "issn": "",
            "pages": "349--350",
            "other_ids": {
                "DOI": [
                    "10.1016/j.dsx.2020.04.019"
                ]
            }
        },
        "BIBREF2": {
            "ref_id": "b2",
            "title": "Aldosterone System Inhibitors in Patients with Covid-19",
            "authors": [
                {
                    "first": "",
                    "middle": [],
                    "last": "Renin-Angiotensin",
                    "suffix": ""
                }
            ],
            "year": 2020,
            "venue": "N Engl J Med",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {
                "DOI": [
                    "10.1056/NEJMsr2005760."
                ]
            }
        },
        "BIBREF3": {
            "ref_id": "b3",
            "title": "Association of inpatient use of angiotensin converting enzyme inhibitors and angiotensin II receptor blockers with mortality among patients with hypertension hospitalized with COVID-19",
            "authors": [
                {
                    "first": "P",
                    "middle": [],
                    "last": "Zhang",
                    "suffix": ""
                },
                {
                    "first": "L",
                    "middle": [],
                    "last": "Zhu",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [],
                    "last": "Cai",
                    "suffix": ""
                },
                {
                    "first": "F",
                    "middle": [],
                    "last": "Lei",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [
                        "J"
                    ],
                    "last": "Qin",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [],
                    "last": "Xie",
                    "suffix": ""
                }
            ],
            "year": null,
            "venue": "Circ Res",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF5": {
            "ref_id": "b5",
            "title": "Different cross-talk sites between the renin-angiotensin and the kallikreinkinin systems",
            "authors": [
                {
                    "first": "J",
                    "middle": [
                        "B"
                    ],
                    "last": "Su",
                    "suffix": ""
                }
            ],
            "year": 2014,
            "venue": "J Renin Angiotensin Aldosterone Syst",
            "volume": "15",
            "issn": "",
            "pages": "319--347",
            "other_ids": {
                "DOI": [
                    "10.1177/1470320312474854"
                ]
            }
        },
        "BIBREF6": {
            "ref_id": "b6",
            "title": "Relation between use of angiotensin-converting enzyme inhibitors and muscle strength and physical function in older women: an observational study",
            "authors": [
                {
                    "first": "G",
                    "middle": [],
                    "last": "Onder",
                    "suffix": ""
                },
                {
                    "first": "B",
                    "middle": [
                        "W"
                    ],
                    "last": "Penninx",
                    "suffix": ""
                },
                {
                    "first": "R",
                    "middle": [],
                    "last": "Balkrishnan",
                    "suffix": ""
                },
                {
                    "first": "L",
                    "middle": [
                        "P"
                    ],
                    "last": "Fried",
                    "suffix": ""
                },
                {
                    "first": "P",
                    "middle": [
                        "H"
                    ],
                    "last": "Chaves",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [],
                    "last": "Williamson",
                    "suffix": ""
                },
                {
                    "first": "C",
                    "middle": [],
                    "last": "Carter",
                    "suffix": ""
                },
                {
                    "first": "Di",
                    "middle": [],
                    "last": "Bari",
                    "suffix": ""
                },
                {
                    "first": "M",
                    "middle": [],
                    "last": "Guralnik",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [
                        "M"
                    ],
                    "last": "Pahor",
                    "suffix": ""
                },
                {
                    "first": "M",
                    "middle": [],
                    "last": "",
                    "suffix": ""
                }
            ],
            "year": 2002,
            "venue": "Lancet",
            "volume": "359",
            "issn": "",
            "pages": "926--956",
            "other_ids": {}
        }
    },
    "ref_entries": {},
    "back_matter": [
        {
            "text": "Dr. Timur Ekiz reports no conflict of interest.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Conflict of interest Statement"
        },
        {
            "text": "Dr. Levent \u00d6z\u00e7akar reports no conflict of interest.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Dr. Murat Kara reports no conflict of interest."
        }
    ]
}